Document is current
Any future updates will be listed below
-
Authors
Oyebanji, Oladayo A.
Yin, Anna
Sundheimer, Nicholas
Ragavapuram, Vaishnavi
Shea, Patrick
Cao, Yi
Chan, Philip A.
Nanda, Aman
Tyagi, Rohit
Raza, Sakeena
Mujahid, Nadia
Abul, Yasin
Balazs, Alejandro B.
Bosch, Jürgen
King, Christopher L.
Klein, Sabra L.
Gravenstein, Stefan
Canaday, David H.
Wilson, Brigid M.
-
Funding
Funding for this research was provided by:
National Institutes of Health (AI129709-03S1)
Centers for Disease Control and Prevention (200-2016-91773)
U.S. Department of Veterans Affairs (BX005507-0.)
- License Information
-
More Information
Article History
Received: 14 August 2024
Accepted: 20 February 2025
First Online: 8 March 2025
Declarations
:
: This study was approved by the Western-Copernicus Group Institutional Review Board (WCG IRB). All participating residents or their legally authorized representatives provided informed consent to be enrolled.
: Not applicable.
: Stefan Gravenstein (S.G) and David H. Canaday (D.H.C) receive investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines and Sanofi Pasteur to study influenza vaccines. S.G. also consults for Astra Zeneca, GlaxoSmithKline, Janssen, Moderna, Novavax, Pfizer, Sanofi, Seqirus, and Vaxart and has received honoraria for speaking engagements from Astra Zeneca, Janssen, Moderna, Novavax, Pfizer, Sanofi, and Seqirus.
